Business Context and Reporting Period
Company: Relmada Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 17, 2019
Reporting Period: The filing reports on capital raising activities occurring in June 2019, referencing a proforma balance sheet as of March 31, 2019.
Key Financial Metrics
This filing details a private placement of securities rather than standard operating results. Key capital metrics include:
- Total Gross Proceeds: Approximately $11.8 million (comprising $11.4 million from prior closings and $0.4 million from the June 28, 2019 closing).
- Securities Issued (June 28, 2019 Closing): 286,756 shares of common stock and 143,377 warrants.
- Liquidity Impact: The company received net proceeds from these offerings, reflected in an attached proforma balance sheet.
- Operating Metrics: Revenue, profit, cash flow from operations, and margins are not provided in this specific filing.
Material Changes
The primary material change is the increase in cash and equity capital resulting from the completion of a securities offering. The filing confirms the finalization of a transaction previously disclosed in a Form 10-Q (filed May 15, 2019) and a prior Form 8-K (filed June 20, 2019), with an additional closing on June 28, 2019.
Guidance, Outlook, and Risks
Management Commentary: The filing serves to update investors on the successful closing of the securities purchase agreements and the receipt of proceeds. No forward-looking guidance, strategic outlook, or specific risk factors are detailed in this text.
Unusual Items: None reported beyond the standard capital raise activity.
Investor Verification Checklist
- Verify the total number of shares and warrants outstanding post-closing by reviewing the proforma balance sheet (Exhibit 99.1).
- Confirm the exact net proceeds received after deducting offering costs, as only gross proceeds are stated in the text.
- Review the terms of the warrants issued (exercise price, expiration) in the underlying Securities Purchase Agreements.
- Check subsequent filings for the impact of these proceeds on the company's cash runway and operational milestones.